Here are the 10-Q quarterly reports from Clearside Biomedical, Inc. (CLSD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CLSD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLSD filings page.
Clearside Biomedical filed its Q3 2025 report highlighting tightening liquidity and a strategic review. Cash and cash equivalents were $6.8 million as of September 30, 2025, and management stated these conditions raise substantial doubt about the company’s ability to continue as a going concern. In July, all employees were terminated and transitioned to consulting roles, incurring $2.3 million in severance, while internal R&D was paused during the review.
Quarterly license and other revenue was $201,000 (vs. $1.04 million a year ago). Net loss for Q3 was $6.0 million (vs. $7.7 million). For the nine months, net loss was $18.7 million (vs. $27.0 million). Operating cash use was $16.0 million year-to-date.
The company effected a 1-for-15 reverse stock split on September 12, 2025, and reported 5,233,981 shares outstanding as of November 12, 2025. It amended its royalty sale with HCR, receiving $2.9 million and reducing the cap to $106.5 million. An at-the-market program raised $1.4 million year-to-date. Health Canada approved XIPERE in July 2025; commercialization economics are subject to the royalty sale structure.
Clearside Biomedical (CLSD) reported cash and cash equivalents of $9.4 million as of June 30, 2025 and total assets of $15.3 million, against total liabilities of $64.1 million, driven largely by a $55.7 million liability related to the sale of future royalties. The company recorded a $12.7 million net loss for the six months ended June 30, 2025 and an accumulated deficit of $368.0 million. License and other revenue for the six months was $2.8 million, including a $1.5 million milestone from Arctic Vision.
In July 2025 the company initiated a formal strategic review and retained Piper Sandler, paused internal R&D and implemented a workforce reduction, estimating third-quarter severance charges of approximately $2.6 million. Management states that, based on current plans, cash on hand is insufficient to fund operations for the next 12 months, and the company disclosed substantial doubt about its ability to continue as a going concern. The company also failed to regain Nasdaq's $1.00 minimum bid requirement and expects a delisting notice, while seeking stockholder approval for a possible reverse split.